If you're facing an insurance denial after a provider like Hims moved away from compounded GLP-1s, you have real appeal options — and a cash-pay bridge doesn't have to mean waiting on approval.
Compounded semaglutide ($197/month) and tirzepatide ($297/month) remain available through Luma Health for patients with a documented individual clinical basis, without needing insurance approval.
Many patients researching insurance denial help right now are in a specific situation: they were using a compounded GLP-1 program that's since scaled back or discontinued that offering following the FDA's 2024-2025 shortage resolutions, and they're now trying to access brand-name medication through insurance instead — often for the first time. Here's how that process actually works.
Why More Patients Are Turning to Insurance Now
Following the FDA's determination that the tirzepatide and semaglutide shortages were resolved (December 2024 and February 2025, respectively), the legal basis for widespread cost-driven compounding narrowed considerably, and several telehealth platforms scaled back or discontinued their compounded GLP-1 offerings. Patients who'd been on an affordable compounded plan suddenly needed a new path — and for many, that means navigating insurance and prior authorization for the first time.
Common Reasons for Denial
The most frequent denial reasons are: missing documentation of BMI and weight-related comorbidities, a plan-level exclusion of weight-loss medications as a category, a formulary change (some pharmacy benefit managers have shifted preferred GLP-1 products), or a step-therapy requirement to try other treatments first. Understanding which applies to your specific denial changes what your appeal should focus on.
Building an Effective Appeal
A strong appeal directly addresses the specific reason in your denial letter, and typically includes a letter of medical necessity from your prescribing provider, documentation of your BMI and relevant comorbidities, and reference to your insurer's own coverage criteria showing how you meet them. Published data suggests a meaningful majority of well-documented appeals succeed. Most commercial plans allow up to 180 days to file an internal appeal — check your specific denial letter for your exact deadline.
Tirzepatide (as Zepbound) carries a separate FDA approval for moderate-to-severe obstructive sleep apnea in adults with obesity. If you have documented or suspected sleep apnea, this pathway can sometimes unlock coverage even when a plan otherwise excludes weight-management-only indications.
Bridging the Gap While Insurance Gets Sorted Out
Appeals and prior authorizations can take anywhere from a couple of weeks to well over a month. Rather than pausing treatment during that window, many patients use a cash-pay bridge — either brand-name self-pay pricing (LillyDirect vials for Zepbound commonly run $299-$449/month by dose) or compounded medication through a licensed 503A pharmacy where a genuine individual clinical basis applies. Compounded semaglutide and tirzepatide remain legally available in 2026 under these narrower conditions, even though the blanket cost-driven compounding of the shortage era has ended.
What to Do Next
- Missing documentation you can now provide
- A step-therapy requirement you can address
- A formulary change where a clinical exception might apply
- You've lost access to a compounded program and need continuity now
- Your plan has a blanket weight-loss exclusion
- You want to avoid a treatment gap while an appeal is pending
Continuity while you
sort out insurance
Compounded semaglutide at $197/month or tirzepatide at $297/month — a real medical evaluation, no insurance approval required.
Get Started → Or start your free health assessmentFrequently Asked Questions
Likely because the FDA's 2024-2025 shortage resolutions narrowed the legal basis for cost-driven compounding, prompting many providers to scale back or discontinue compounded GLP-1 offerings and shift patients toward brand-name, insurance-based options.
Most commercial plans allow up to 180 days from your denial letter, though some plans have shorter windows. Check your specific letter for the exact deadline.
A letter of medical necessity, documentation of BMI and comorbidities, and a direct response to the specific reason cited in your denial letter, referencing your insurer's own coverage criteria.
Possibly. Tirzepatide (Zepbound) has a separate FDA approval for moderate-to-severe obstructive sleep apnea in adults with obesity, which can sometimes unlock coverage even when weight-management-only indications are excluded.
It can be, if there's a genuine documented individual clinical basis for compounding rather than using the commercial product — this is narrower than the blanket cost-driven compounding available during the shortage era, but it remains a legal pathway in 2026.
Most plans allow a second-level review, and employer plans governed by ERISA provide a right to external review by an independent reviewer if internal appeals don't resolve the issue.
References
- U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. FDA.gov. 2025. FDA.gov
- Malhotra A, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA). N Engl J Med. 2024;391(13):1193-1205. PubMed 38912654
- American Medical Association. Prior authorization resources. AMA-assn.org. AMA-assn.org
- U.S. Food and Drug Administration. Human Drug Compounding and the FD&C Act. FDA.gov. FDA.gov
- Mercer. National Survey of Employer-Sponsored Health Plans, 2025: GLP-1 coverage findings. Mercer.com. 2025. Mercer.com